|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.34 EUR | 0.00% |
|
-1.48% | -24.76% |
| 06-09 | Buy-side pressure on MIB; Unipol and BPER lead gains | AN |
| 06-08 | Clínica Baviera, the copy-paste machine |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.91 | 5.03 | 4.72 | 4.33 | 3.67 | |||||
Return on Total Capital | 6.73 | 7 | 6.63 | 6.03 | 5.06 | |||||
Return On Equity % | 18.92 | 18.17 | 14.47 | 12.93 | 8.52 | |||||
Return on Common Equity | 18.95 | 18.18 | 14.5 | 12.92 | 8.5 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 25.01 | 24.91 | 24.27 | 24.11 | 23.52 | |||||
SG&A Margin | 0.5 | 0.58 | 0.71 | 0.82 | 0.84 | |||||
EBITDA Margin % | 19.84 | 19.67 | 17 | 16.1 | 14.98 | |||||
EBITA Margin % | 17.44 | 17.25 | 14.6 | 13.54 | 12.22 | |||||
EBIT Margin % | 13.6 | 13.47 | 12.14 | 11.05 | 9.67 | |||||
Income From Continuing Operations Margin % | 8.4 | 8.44 | 6.86 | 6.04 | 3.82 | |||||
Net Income Margin % | 8.1 | 8.42 | 6.86 | 6.03 | 3.81 | |||||
Net Avail. For Common Margin % | 8.39 | 8.42 | 6.86 | 6.03 | 3.81 | |||||
Normalized Net Income Margin | 7.73 | 7.38 | 6.18 | 5.36 | 4.33 | |||||
Levered Free Cash Flow Margin | 16.09 | 15.96 | 14.2 | 12.86 | 12.32 | |||||
Unlevered Free Cash Flow Margin | 16.98 | 16.86 | 15.44 | 14.36 | 13.88 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.58 | 0.6 | 0.62 | 0.63 | 0.61 | |||||
Fixed Assets Turnover | 3.22 | 3.34 | 3.36 | 3.33 | 3.32 | |||||
Receivables Turnover (Average Receivables) | 11.54 | 11.75 | 10.68 | 10.52 | 10.68 | |||||
Inventory Turnover (Average Inventory) | 24.35 | 22.93 | 20.8 | 20.15 | 20.86 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.73 | 0.56 | 0.53 | 0.62 | 0.61 | |||||
Quick Ratio | 0.58 | 0.4 | 0.42 | 0.51 | 0.49 | |||||
Operating Cash Flow to Current Liabilities | 0.52 | 0.43 | 0.35 | 0.39 | 0.33 | |||||
Days Sales Outstanding (Average Receivables) | 31.64 | 31.07 | 34.18 | 34.79 | 34.17 | |||||
Days Outstanding Inventory (Average Inventory) | 14.99 | 15.92 | 17.55 | 18.17 | 17.49 | |||||
Average Days Payable Outstanding | 52.72 | 64.6 | 72.48 | 73.48 | 74.5 | |||||
Cash Conversion Cycle (Average Days) | -6.09 | -17.61 | -20.75 | -20.52 | -22.84 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 174.35 | 145.26 | 138.34 | 151.63 | 183.23 | |||||
Total Debt / Total Capital | 63.55 | 59.23 | 58.04 | 60.26 | 64.69 | |||||
LT Debt/Equity | 147.35 | 112.25 | 99.32 | 116.49 | 135.01 | |||||
Long-Term Debt / Total Capital | 53.71 | 45.77 | 41.67 | 46.29 | 47.67 | |||||
Total Liabilities / Total Assets | 73.62 | 70.9 | 70.17 | 71.19 | 74.35 | |||||
EBIT / Interest Expense | 9.57 | 9.3 | 6.15 | 4.61 | 3.88 | |||||
EBITDA / Interest Expense | 17.44 | 17.12 | 11.29 | 8.99 | 8.35 | |||||
(EBITDA - Capex) / Interest Expense | 15.57 | 15.26 | 9.6 | 7.52 | 7.41 | |||||
Total Debt / EBITDA | 3.35 | 2.88 | 3.03 | 3.36 | 3.67 | |||||
Net Debt / EBITDA | 2.79 | 2.54 | 2.64 | 2.8 | 3.05 | |||||
Total Debt / (EBITDA - Capex) | 3.75 | 3.23 | 3.56 | 4.01 | 4.14 | |||||
Net Debt / (EBITDA - Capex) | 3.13 | 2.84 | 3.11 | 3.35 | 3.44 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 29.59 | 8.78 | 6.65 | 6.6 | -0.56 | |||||
Gross Profit, 1 Yr. Growth % | 35.01 | 8.12 | 4.29 | 5.92 | -2.95 | |||||
EBITDA, 1 Yr. Growth % | 40.02 | 7.82 | -7.87 | -8.15 | -17.67 | |||||
EBITA, 1 Yr. Growth % | 48.75 | 7.64 | -9.86 | -11.35 | -21.74 | |||||
EBIT, 1 Yr. Growth % | 58.77 | 7.76 | -4 | -2.96 | -12.92 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 69.23 | 9.28 | -13.29 | -6.1 | -37.11 | |||||
Net Income, 1 Yr. Growth % | 56.22 | 13.14 | -13.1 | -6.29 | -37.17 | |||||
Normalized Net Income, 1 Yr. Growth % | 75.23 | 5.18 | -10.81 | -7.6 | -19.43 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 68.8 | 9.39 | -12.57 | -6.68 | -37.17 | |||||
Accounts Receivable, 1 Yr. Growth % | -0.22 | 13.86 | 20.4 | -1.95 | -2.18 | |||||
Inventory, 1 Yr. Growth % | 8.95 | 21.88 | 15.82 | 5.5 | -11.51 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 6.35 | 3.35 | 8.45 | 6.62 | -6.28 | |||||
Total Assets, 1 Yr. Growth % | 8.88 | 1.71 | 3.29 | 8.11 | -2.5 | |||||
Tangible Book Value, 1 Yr. Growth % | 39.07 | -3.01 | -1.79 | 9.74 | 7.02 | |||||
Common Equity, 1 Yr. Growth % | 15.52 | 12.25 | 6.01 | 4.46 | -13.2 | |||||
Cash From Operations, 1 Yr. Growth % | 18.11 | -0.81 | -9.83 | 9.1 | -8.13 | |||||
Capital Expenditures, 1 Yr. Growth % | 71.96 | 9.8 | 32.53 | 12.78 | -33.63 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -3.38 | 7.85 | -5.15 | -3.48 | -4.64 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -3.35 | 8.01 | -2.43 | -0.84 | -3.81 | |||||
Dividend Per Share, 1 Yr. Growth % | 18.18 | 11.54 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.05 | 18.73 | 7.71 | 6.63 | 2.96 | |||||
Gross Profit, 2 Yr. CAGR % | 10.23 | 20.94 | 5.99 | 5.1 | 1.36 | |||||
EBITDA, 2 Yr. CAGR % | 12.6 | 22.87 | -0.29 | -3.57 | -7.83 | |||||
EBITA, 2 Yr. CAGR % | 13.67 | 26.54 | -1.45 | -5.6 | -10.8 | |||||
EBIT, 2 Yr. CAGR % | 14.43 | 30.8 | 1.77 | -3.48 | -8.13 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 22.78 | 35.99 | -2.66 | -9.76 | -23.15 | |||||
Net Income, 2 Yr. CAGR % | 20.5 | 32.95 | -0.84 | -9.76 | -23.27 | |||||
Normalized Net Income, 2 Yr. CAGR % | 16.96 | 34.95 | -3.08 | -9.22 | -13.79 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 22.25 | 35.89 | -2.2 | -9.67 | -23.43 | |||||
Accounts Receivable, 2 Yr. CAGR % | -9.34 | 6.59 | 17.09 | 8.66 | -2.06 | |||||
Inventory, 2 Yr. CAGR % | -1.58 | 15.23 | 18.81 | 10.54 | -3.38 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 0.75 | 4.84 | 5.87 | 7.53 | -0.04 | |||||
Total Assets, 2 Yr. CAGR % | 11.03 | 5.24 | 2.5 | 5.67 | 2.67 | |||||
Tangible Book Value, 2 Yr. CAGR % | 14.83 | 16.14 | -2.4 | 3.81 | 8.37 | |||||
Common Equity, 2 Yr. CAGR % | 15.37 | 13.87 | 9.08 | 5.23 | -4.78 | |||||
Cash From Operations, 2 Yr. CAGR % | 20.32 | 8.24 | -5.43 | -0.82 | 0.11 | |||||
Capital Expenditures, 2 Yr. CAGR % | 1.24 | 37.41 | 20.63 | 22.26 | -13.48 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 16.87 | 2.08 | 1.18 | -4.31 | -4.09 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 16.03 | 2.17 | 2.69 | -1.64 | -2.36 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | 14.81 | 5.61 | 0 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 12.66 | 6.95 | 14.56 | 7.34 | 4.17 | |||||
Gross Profit, 3 Yr. CAGR % | 16.78 | 9.6 | 14.98 | 5.97 | 2.33 | |||||
EBITDA, 3 Yr. CAGR % | 18.22 | 10.99 | 11.66 | 0.11 | -4.9 | |||||
EBITA, 3 Yr. CAGR % | 19.39 | 11.62 | 13.05 | -1.34 | -7.17 | |||||
EBIT, 3 Yr. CAGR % | 17.68 | 12.16 | 18.04 | 0.17 | -6.77 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 17.67 | 18.1 | 17.05 | -3.82 | -20 | |||||
Net Income, 3 Yr. CAGR % | 16.25 | 18 | 15.38 | -2.69 | -20.02 | |||||
Normalized Net Income, 3 Yr. CAGR % | 17.42 | 12.45 | 17.6 | -4.61 | -12.8 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 17.1 | 17.81 | 17.31 | -3.72 | -19.97 | |||||
Accounts Receivable, 3 Yr. CAGR % | -0.15 | -2.18 | 11.01 | 10.36 | 4.92 | |||||
Inventory, 3 Yr. CAGR % | 0.46 | 5.69 | 15.43 | 14.2 | 2.64 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 48.93 | 1.61 | 6.03 | 6.12 | 2.71 | |||||
Total Assets, 3 Yr. CAGR % | 15.94 | 7.84 | 4.58 | 4.34 | 2.88 | |||||
Tangible Book Value, 3 Yr. CAGR % | 8.13 | 8.54 | 9.82 | 1.49 | 4.87 | |||||
Common Equity, 3 Yr. CAGR % | 15.86 | 14.32 | 11.19 | 7.52 | -1.31 | |||||
Cash From Operations, 3 Yr. CAGR % | 36.76 | 12.82 | 1.85 | -0.81 | -3.32 | |||||
Capital Expenditures, 3 Yr. CAGR % | 2.46 | 4.02 | 35.76 | 17.96 | -0.27 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 24.36 | 13.79 | -0.36 | -0.4 | -4.44 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 24.55 | 13.29 | 0.63 | 1.5 | -2.39 | |||||
Dividend Per Share, 3 Yr. CAGR % | 22.92 | - | 9.65 | 3.71 | 0 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 11.45 | 10.85 | 10.66 | 6.82 | 9.77 | |||||
Gross Profit, 5 Yr. CAGR % | 14.23 | 13.21 | 12.39 | 7.7 | 9.32 | |||||
EBITDA, 5 Yr. CAGR % | 15.34 | 13.91 | 10.44 | 4.94 | 5.38 | |||||
EBITA, 5 Yr. CAGR % | 15.91 | 14.41 | 10.57 | 4.41 | 5.09 | |||||
EBIT, 5 Yr. CAGR % | 14.12 | 12.88 | 11.04 | 5.65 | 6.78 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 20.73 | 12.21 | 9.07 | 6.05 | -1.08 | |||||
Net Income, 5 Yr. CAGR % | 19.92 | 12.16 | 9.08 | 5.99 | -1.99 | |||||
Normalized Net Income, 5 Yr. CAGR % | 15.79 | 12.89 | 8.49 | 3.25 | 3.87 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 20.55 | 11.94 | 8.96 | 5.93 | -1.09 | |||||
Accounts Receivable, 5 Yr. CAGR % | 5.79 | 7.66 | 6.42 | 2.02 | 5.58 | |||||
Inventory, 5 Yr. CAGR % | 14.81 | 15.51 | 7.43 | 7.6 | 7.5 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 39.12 | 35.17 | 29.93 | 3.94 | 3.56 | |||||
Total Assets, 5 Yr. CAGR % | 20.12 | 19.53 | 10.36 | 6.97 | 3.81 | |||||
Tangible Book Value, 5 Yr. CAGR % | 37.33 | 30.86 | 3.79 | 6.63 | 9.24 | |||||
Common Equity, 5 Yr. CAGR % | 10.67 | 12.02 | 13.1 | 10.6 | 4.5 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.33 | 22.11 | 18 | 7.15 | 1.15 | |||||
Capital Expenditures, 5 Yr. CAGR % | 3.01 | 2.25 | 9.38 | 10.96 | 13.37 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 28.76 | 30.3 | 14.51 | 6.18 | -1.87 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 26.99 | 28.56 | 15.3 | 7.08 | -0.58 | |||||
Dividend Per Share, 5 Yr. CAGR % | 30.01 | 21.4 | 15.68 | - | 5.68 |
- Stock Market
- Stocks
- AMP Stock
- Financials Amplifon S.p.A.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















